» Articles » PMID: 34894008

Association Between Serum Hemoglobin and Major Cardiovascular Adverse Event in Chinese Patients with ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2021 Dec 11
PMID 34894008
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: ST-segment elevation myocardial infarction (STEMI) is a common clinical acute and severe disease, and it is of great significance to evaluate the prognosis of these patients. Hemoglobin levels are associated with a variety of diseases, but studies on Chinese patients with STEMI after percutaneous coronary intervention (PCI) have not been sufficient.

Methods: This was a secondary analysis based on a prospective cohort study of patients undergoing PCI in Taizhou, Zhejiang, China. We performed multivariable logistic regression to explore the association between the serum hemoglobin and the incidence of major cardiovascular adverse event (MACE) in patients after PCI. We also used a generalized additive model and smooth curve fitting to explain the nonlinear relationship after adjusting the potential confounders. Finally, the heterogeneity among specific groups was examined by subgroup analysis.

Results: Of all 462 patients enrolled in this study, 118 (25.54%) developed MACE. There was a negative correlation between serum hemoglobin and MACE in all three models (hazard ratio [HR] 0.82, 95% confidence interval [CI 0.72, 0.93], HR 0.86, 95% CI [0.76,0.98], and HR 0.87, 95% CI [0.74,0.98], respectively). In the subgroup analysis, the negative correlation existed between the patients who had myocardial infarction (MI) history (p for interaction = 0.0059) after adjusting covariates. However, no significant differences were found between age and sex groups (p for interaction = 0.1381, 0.4103, respectively).

Conclusion: Our results indicated that patients who received PCI with low preoperative hemoglobin were more likely to develop MACE, especially if they have already had a history of MI.

Citing Articles

Enhanced predictive performance of the GRACE risk score by incorporating lipoprotein(a) for major adverse cardiac events in acute myocardial infarction patients undergoing PCI.

Cheng X, Liu M, Wang Q, Xu Y, Liu R, Li X Int J Cardiol Cardiovasc Risk Prev. 2024; 22:200315.

PMID: 39157191 PMC: 11327944. DOI: 10.1016/j.ijcrp.2024.200315.


Age and gender mediated the association between anemia and 30-day outcomes in patients with ST-segment elevated myocardial infarction.

Wang S, Zhang Y, Qi D, Wang X, Zhu Z, Yang W Int J Cardiol Heart Vasc. 2024; 51:101377.

PMID: 38464962 PMC: 10920728. DOI: 10.1016/j.ijcha.2024.101377.


Rosuvastatin plus ticagrelor decreases the risk of major adverse cardiovascular events and elevates cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention: A meta‑analysis.

Sun J, Jin X, Zhang L, Shen H, Yu H Exp Ther Med. 2023; 26(5):525.

PMID: 37869634 PMC: 10587883. DOI: 10.3892/etm.2023.12224.


Association between serum hemoglobin and major cardiovascular adverse event in Chinese patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention.

Yang Y, Huang Y J Clin Lab Anal. 2021; 36(1):e24126.

PMID: 34894008 PMC: 8761445. DOI: 10.1002/jcla.24126.

References
1.
Bulluck H, Zheng H, Chan M, Foin N, Foo D, Lee C . Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention. Sci Rep. 2019; 9(1):10072. PMC: 6624280. DOI: 10.1038/s41598-019-46486-0. View

2.
Farhan S, Baber U, Mehran R . Anemia and Acute Coronary Syndrome: Time for Intervention Studies. J Am Heart Assoc. 2016; 5(11). PMC: 5210317. DOI: 10.1161/JAHA.116.004908. View

3.
Zhang E, Li Z, Che J, Chen X, Qin T, Tong Q . Anemia and Inflammation in ST-Segment Elevation Myocardial Infarction. Am J Med Sci. 2015; 349(6):493-8. PMC: 4450907. DOI: 10.1097/MAJ.0000000000000471. View

4.
Al-Hijji M, Gulati R, Lennon R, Bell M, El Sabbagh A, Park J . Outcomes of Percutaneous Coronary Interventions in Patients With Anemia Presenting With Acute Coronary Syndrome. Mayo Clin Proc. 2018; 93(10):1448-1461. DOI: 10.1016/j.mayocp.2018.03.030. View

5.
Wang H, Liu Z, Shao J, Lin L, Jiang M, Wang L . Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications. J Immunol Res. 2020; 2020:4904217. PMC: 7450309. DOI: 10.1155/2020/4904217. View